Zoetis (NYSE:ZTS) Reaches New 1-Year Low – Here’s Why

Shares of Zoetis Inc. (NYSE:ZTS) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $112.10 and last traded at $112.8090, with a volume of 3211457 shares trading hands. The stock had previously closed at $114.16.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ZTS shares. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. UBS Group dropped their price objective on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Bank of America upped their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Citigroup started coverage on shares of Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price objective on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $151.75.

Zoetis Price Performance

The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a market capitalization of $46.92 billion, a P/E ratio of 18.53, a P/E/G ratio of 1.73 and a beta of 0.87. The company’s 50-day simple moving average is $119.33 and its 200 day simple moving average is $124.10.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.61 by ($0.08). Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Institutional Trading of Zoetis

Several large investors have recently modified their holdings of the company. Valley Wealth Managers Inc. boosted its holdings in shares of Zoetis by 148.1% during the 1st quarter. Valley Wealth Managers Inc. now owns 670 shares of the company’s stock worth $79,000 after buying an additional 400 shares during the period. Mediolanum International Funds Ltd boosted its holdings in shares of Zoetis by 8.2% during the 1st quarter. Mediolanum International Funds Ltd now owns 191,495 shares of the company’s stock worth $22,277,000 after buying an additional 14,539 shares during the period. Spartan Wealth Advisory Services LLC bought a new stake in shares of Zoetis during the 1st quarter worth $784,000. German American Bancorp Inc. boosted its holdings in shares of Zoetis by 8.1% during the 1st quarter. German American Bancorp Inc. now owns 20,291 shares of the company’s stock worth $2,399,000 after buying an additional 1,512 shares during the period. Finally, Clifford Swan Investment Counsel LLC boosted its holdings in shares of Zoetis by 115.7% during the 1st quarter. Clifford Swan Investment Counsel LLC now owns 148,151 shares of the company’s stock worth $17,513,000 after buying an additional 79,463 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.